Construction of a Single ComponentProducer from the Wild Type Avermectin Producer Streptomyces avermitilis
Sir:
Most microbial secondary metabolites are producec as complexes of closely related compounds by theii producing organisms. The avermectins1*, milbemycins2 and nemadectins3~5) are typical examples produced ii such a manner. The milbemyciif complex is known t( consist of more than twenty components6~8), however only a few are commercial products. A rationale for thii phenomenon may be related to the complexity of thei biosyntheses and/or lower degrees of substrate speci ficities of the biosynthetic enzymes. The avermectin complex is a family of eight closely related component as shown in Fig. 1 , which is produced chemically from avermectin B2a, to be the most potent anthelmintic compound11}. Therefore, a single component producer of avermectin B2a would be assumed to be extremely useful for industrial production of ivermectin Bla. As we had already constructed a recombinant strain K2038 (aveD X), a producer of avermectins Bla and B2a12) ( Fig. 2-A) , our goal was expected to be accomplished by introducing only one mutation, aveC, into the recombinant strain.
In the present communication, we describe a single component (avermectin B2a) producer derived from Streptomyces avermitilis by two approaches, in vivo and in vitro mutagenesis of the aveC region. Mutagenesis and culture conditions of S. avermitilis were performed as described by us13 '14) . Mycelial products were analyzed by silica gel thin layer chromatography or HPLC as described previously*2~14).
In the first approach, we treated recombinant strain K2038 with A^methyl-N'-nitro-A^nitrosoguanidine and isolated a single componentavermectin B2a producer (mutant H48), from several thousand clones. Since the 
Both sugars are a-L-oleandrose. Ivermectin is chemically synthesized from avermectin Bl components (Bla and Bib) by selective hydrogenation1 1* and commercial ivermectin consists of more than 80%ivermectin Bla and less than 20%ivermectin
Bib.
VOL. 48 NO. 6 THE JOURNAL OF ANTIBIOTICS 533 Fig. 2 . Analytical HPLCchromatograms of the mycelial extracts from the parent strain K2038 (A), its transreplacement clones K2099 (aveC aveD X; B) and K2101 (aveC aveD X olmA :: Tn4560; C).
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The mycelia from a lOml-culture were extracted with an equal volume of acetone and after removal of acetone by evaporation, products were extracted with methylenechloride. The methylenechloride extract was evaporated to dryness, the residue was dissolved in methanol and a portion of the extract was directly applied to reversed phase silica gel HPLC.The separation conditions are described in ref. 12. productivity of the antibiotic by mutant H48 was very low in comparison with that of the parent strain K2038, we considered the mutant to contain other mutation (s) in the genes involving avermectin production.
We tried in vitro mutagenesis as the second approach. As the entire gene cluster for avermectin biosynthesis had been already cloned9 '15) , and the region involving the C-22,23-dehydration step (aveC) had been defined in a 4.82kbp-2taraHI fragment by us, we attempted transition or transversion mutation in the aveC region on the chromosomeof the recombinant strain K2038. As a result, we subcloned a 640bp-Pstl/Sphl fragment in the left side of the BamHl fragment9) containing the aveC region. The resulting fragment was amplified by the polyttierase chain reaction (PCR) in which concentrations of three nucleotides (dCTP, dGTPand dTTP) were increased 4-fold to cause deoxynucleotide misincorporation into synthesized chains by Taq DNA polymerase during the elongation reaction. The amplified fragments of which some would contain transition or transversion mutation due to misincorporation of deoxynucleotides, were exchanged with the corresponding region in the chromosomeby gene transreplacement technique. The resulting transreplacement clone did produce avermectin B2a as the sole avermectin component ( Fig. 2-B) .
To confirm the structures of the products from both single component producers, the mutant H48 and the transreplacement clone (K2099) were cultivated in a liquid production medium as described previously1 3 ' 14) .
Mycelia from each cultured broth were extracted with acetone, and the extracts from which mycelia were removed by filtration, were evaporated under the reduced pressure. Each concentrate was suspended in deionized water and then extracted twice with methylenechloride. Ultimately, the main products of each strain were separated by a preparative HPLC to obtain purified material. Physico-chemical properties of purified materials derived from both mutant strains were identical to those of authentic avermectin B2purified from the wild type strain. Furthermore, XHand 13C NMRdata for purified materials from both strains were identical to avermectin B2a. These producers, however, produced not only avermectin B2a but also oligomycin, which is an unwanted toxic compound.Wehave already established the disruption of oligomycin production without affecting avermectin production by transposon mutagenesis16). That is, a part of the oligomycin biosynthetic region carrying transposon Tn4560 was exchanged with the corresponding region in chromosome of K2099 by gene transreplacement technique. The resulting transreplacement clone (K2101) produced avermectin B2a but not oligomycin (Fig. 2-C) . Thus, a producer (K2101) of avermectin B2a was constructed successfully by specific mutation of the gene for the C-22, 23-dehydration step and by disruption of oligomycin biosynthesis without affecting the productivity of avermectin by the producer, S. avermitilis. As avermectin B2acould be recovered without the separation from other related components, it would become easier to convert avermectin B2a to ivermectin Bla by chemical transformation.
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